Literature DB >> 21544602

Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis.

Kelly F Thomsen1, Michael Laposata, Sarah W Njoroge, Obi C Umunakwe, Waddah Katrangi, Adam C Seegmiller.   

Abstract

Patients with cystic fibrosis, caused by mutations in CFTR, exhibit specific and consistent alterations in the levels of particular unsaturated fatty acids compared with healthy controls. Evidence suggests that these changes may play a role in the pathogenesis of this disease. Among these abnormalities are increases in the levels of n-7 and n-9 fatty acids, particularly palmitoleate (16:1n-7), oleate (18:1n-9), and eicosatrienoate or mead acid (20:3n-9). The underlying mechanisms of these particular changes are unknown, but similar changes in the n-3 and n-6 fatty acid families have been correlated with increased expression of fatty acid metabolic enzymes. This study demonstrated that cystic fibrosis cells in culture exhibit increased metabolism along the metabolic pathways leading to 16:1n-7, 18:1n-9, and 20:3n-9 compared with wild-type cells. Furthermore, these changes are accompanied by increased expression of the enzymes that produce these fatty acids, namely Δ5, Δ6, and Δ9 desaturases and elongases 5 and 6. Taken together, these findings suggest that fatty acid abnormalities of the n-7 and n-9 series in cystic fibrosis are as a result, at least in part, of increased expression and activity of these metabolic enzymes in CFTR-mutated cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544602      PMCID: PMC3711213          DOI: 10.1007/s11745-011-3563-z

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  39 in total

1.  Identification of the cystic fibrosis gene: genetic analysis.

Authors:  B Kerem; J M Rommens; J A Buchanan; D Markiewicz; T K Cox; A Chakravarti; M Buchwald; L C Tsui
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

2.  Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis.

Authors:  B Strandvik; E Gronowitz; F Enlund; T Martinsson; J Wahlström
Journal:  J Pediatr       Date:  2001-11       Impact factor: 4.406

3.  Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis.

Authors:  G Lepage; E Levy; N Ronco; L Smith; N Galéano; C C Roy
Journal:  J Lipid Res       Date:  1989-10       Impact factor: 5.922

4.  Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors.

Authors:  S Rajan; G Cacalano; R Bryan; A J Ratner; C U Sontich; A van Heerckeren; P Davis; A Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2000-09       Impact factor: 6.914

5.  A cystic fibrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection.

Authors:  P L Zeitlin; L Lu; J Rhim; G Cutting; G Stetten; K A Kieffer; R Craig; W B Guggino
Journal:  Am J Respir Cell Mol Biol       Date:  1991-04       Impact factor: 6.914

6.  Defective regulation of outwardly rectifying Cl- channels by protein kinase A corrected by insertion of CFTR.

Authors:  M Egan; T Flotte; S Afione; R Solow; P L Zeitlin; B J Carter; W B Guggino
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

7.  Assessment of essential fatty acid and omega3-fatty acid status by measurement of erythrocyte 20:3omega9 (Mead acid), 22:5omega6/20:4omega6 and 22:5omega6/22:6omega3.

Authors:  M R Fokkema; E N Smit; I A Martini; H A Woltil; E R Boersma; F A J Muskiet
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002-11       Impact factor: 4.006

Review 8.  The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions.

Authors:  Anne Vankeerberghen; Harry Cuppens; Jean-Jacques Cassiman
Journal:  J Cyst Fibros       Date:  2002-03       Impact factor: 5.482

9.  Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gas-liquid chromatography.

Authors:  E N Siguel; K M Chee; J X Gong; E J Schaefer
Journal:  Clin Chem       Date:  1987-10       Impact factor: 8.327

10.  Fatty acid composition of erythrocyte phospholipids from patients with cystic fibrosis.

Authors:  V S Hubbard; G D Dunn
Journal:  Clin Chim Acta       Date:  1980-03-14       Impact factor: 3.786

View more
  11 in total

1.  Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase.

Authors:  Obi C Umunakwe; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2014-05-24       Impact factor: 5.922

2.  The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study.

Authors:  Michael Glenn O'Connor; Adam Seegmiller
Journal:  J Cyst Fibros       Date:  2016-07-26       Impact factor: 5.482

3.  DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity.

Authors:  Sarah W Njoroge; Michael Laposata; Waddah Katrangi; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2011-11-16       Impact factor: 5.922

4.  Interactions of linoleic and alpha-linolenic acids in the development of fatty acid alterations in cystic fibrosis.

Authors:  Waddah Katrangi; Joshua Lawrenz; Adam C Seegmiller; Michael Laposata
Journal:  Lipids       Date:  2013-02-27       Impact factor: 1.880

5.  Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.

Authors:  Jun Yang; Jason P Eiserich; Carroll E Cross; Brian M Morrissey; Bruce D Hammock
Journal:  Free Radic Biol Med       Date:  2012-05-08       Impact factor: 7.376

6.  Tissue expression profiles and transcriptional regulation of elongase of very long chain fatty acid 6 in bovine mammary epithelial cells.

Authors:  Si Chen; Hua He; Xiaolin Liu
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

7.  Determinants of Serum Glycerophospholipid Fatty Acids in Cystic Fibrosis.

Authors:  Sławomira Drzymała-Czyż; Patrycja Krzyżanowska; Berthold Koletzko; Jan Nowak; Anna Miśkiewicz-Chotnicka; Jerzy A Moczko; Aleksandra Lisowska; Jarosław Walkowiak
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

Review 8.  Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.

Authors:  Adam C Seegmiller
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

9.  The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients.

Authors:  Caroline Morin; André M Cantin; Félix-Antoine Vézina; Samuel Fortin
Journal:  Mar Drugs       Date:  2018-05-26       Impact factor: 5.118

10.  Impaired Ratio of Unsaturated to Saturated Non-Esterified Fatty Acids in Saliva from Patients with Cystic Fibrosis.

Authors:  Monica Gelzo; Paola Iacotucci; Vincenzo Carnovale; Alice Castaldo; Marika Comegna; Gustavo Cernera; Gaetano Corso; Giuseppe Castaldo
Journal:  Diagnostics (Basel)       Date:  2020-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.